ArticleInternational urology and nephrology2016
Survival following laparoscopic adrenalectomy for solitary metastasis of lung cancer.
Article in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine if L/S ADX is a safe and effective procedure for the management of solitary adrenal metastasis of lung cancer, and if it improves survival in lung cancer patients. MATERIALS AND
methodsThe medical records of patients that were diagnosed as lung cancer and underwent L/S ADX for suspected adrenal gland metastasis were retrospectively analyzed. Patient demographics, prior interventions and medical treatments for lung cancer, adrenal mass characteristics, surgical features, postoperative course, and histopathological findings were examined.
resultsIn total, 13 patients underwent 15 L/S ADXs due to suspected solitary adrenal metastasis of lung cancer. Mean age of the patients was 60.5 ± 7.3 years. Mean adrenal mass size based on CT was 35 ± 26.9 mm. The surgical margin was tumor-free in eight of the ADXs. Surgical margin positivity was observed in seven ADXs, and local recurrence was observed in only two patients (28.5 %) with surgical margin positivity. Mean estimated survival in the patients with metachronous adrenal metastasis was lower than in those with synchronous adrenal metastasis (33.1 ± 5.4 vs. 33.2 ± 7.5 months, respectively). Estimated survival in the patients with NSCLC was higher than in those with SCLC (33.9 ± 5.7 vs. 24 ± 4.2 months, respectively); the difference was not significant (P = 0.736). Estimated overall survival was 33.4 ± 5.2 months.
conclusionResection of adrenal metastases of lung cancer via L/S ADX could be considered a viable method for achieving disease-free status and prolonging survival, especially in chemo-frayed patients.
Indexed as
Identifiers
27417132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.